Biodesix (BDSX) to Release Quarterly Earnings on Friday

Biodesix (NASDAQ:BDSX) is set to issue its quarterly earnings data before the market opens on Friday, November 1st. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Biodesix has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $17.93 million for the quarter, compared to the consensus estimate of $16.05 million. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. During the same period in the prior year, the business posted ($0.17) earnings per share. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Trading Up 3.1 %

Biodesix stock opened at $1.65 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 3.28 and a quick ratio of 3.28. The company has a market capitalization of $239.54 million, a price-to-earnings ratio of -3.59 and a beta of 1.22. Biodesix has a one year low of $1.15 and a one year high of $2.21. The company’s fifty day moving average price is $1.74 and its two-hundred day moving average price is $1.60.

Analyst Upgrades and Downgrades

BDSX has been the topic of several analyst reports. Craig Hallum initiated coverage on shares of Biodesix in a research report on Friday, July 26th. They set a “buy” rating and a $3.00 target price on the stock. Scotiabank started coverage on shares of Biodesix in a report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.